FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384704944> ?p ?o ?g. }

• W4384704944 abstract "New regimens may provide better tolerability, convenience, and safety for nonoccupational human immunodeficiency virus (HIV) postexposure prophylaxis (PEP). For this reason, we evaluated the single-tablet regimen of doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) for 28 days.This was a prospective, open-label, single-arm trial including individuals with potential HIV-1 exposure within 72 hours. The primary endpoint was noncompletion of PEP at day 28. Secondary endpoints were adverse effects, adherence, and rate of seroconversion. We performed follow-up at day 7, week 4, and week 12.Between September 2019 and March 2022, the study enrolled 399 individuals. Median age was 30 (interquartile range [IQR], 27-36) years, and 91% (n = 364) were male. The mode of exposure was sex between men in 84% (n = 331) of cases; risk assessment for HIV-1 transmission was considered as high in 97% (n = 385) of the participants. Median time from exposure to consultation was 24 (IQR, 13-40) hours. Noncompletion of PEP was 29% (n = 114) (95% confidence interval [CI], 24%-33%) and 20% (n = 72) (95% CI, 16%-25%) per modified intention-to-treat. Main reasons for noncompletion were loss to follow-up (n = 104 [91%]) and intolerance (n = 8 [7%]). Older age was associated with a lower risk of premature discontinuation (OR, 0.94; P < .001). One hundred twenty-three (31%) participants reported adverse events, mostly mild and self-limited (82%); discontinuation occurred in 8 cases (2%). Adherence to PEP in the assessed users was 96%. There were no HIV seroconversions.DOR/3TC/TDF is a well-tolerated option for nonoccupational PEP. Clinical Trials Registration. NCT04233372." @default.
• W4384704944 created "2023-07-20" @default.
• W4384704944 creator A5000526175 @default.
• W4384704944 creator A5001007615 @default.
• W4384704944 creator A5002398661 @default.
• W4384704944 creator A5008314944 @default.
• W4384704944 creator A5018384098 @default.
• W4384704944 creator A5021697174 @default.
• W4384704944 creator A5026597427 @default.
• W4384704944 creator A5033344017 @default.
• W4384704944 creator A5034162338 @default.
• W4384704944 creator A5035485013 @default.
• W4384704944 creator A5036857685 @default.
• W4384704944 creator A5037782010 @default.
• W4384704944 creator A5042051995 @default.
• W4384704944 creator A5044869929 @default.
• W4384704944 creator A5057724971 @default.
• W4384704944 creator A5060309869 @default.
• W4384704944 creator A5061281956 @default.
• W4384704944 creator A5070081054 @default.
• W4384704944 creator A5070507509 @default.
• W4384704944 creator A5075698856 @default.
• W4384704944 creator A5079522703 @default.
• W4384704944 creator A5081538828 @default.
• W4384704944 creator A5082838507 @default.
• W4384704944 creator A5083203472 @default.
• W4384704944 creator A5085047733 @default.
• W4384704944 creator A5087851609 @default.
• W4384704944 creator A5088119944 @default.
• W4384704944 creator A5089446001 @default.
• W4384704944 creator A5092496270 @default.
• W4384704944 creator A5092496271 @default.
• W4384704944 date "2023-07-19" @default.
• W4384704944 modified "2023-10-14" @default.
• W4384704944 title "Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate for Nonoccupational HIV-1 Postexposure Prophylaxis: A Prospective Open-Label Trial (DORAVIPEP)" @default.
• W4384704944 cites W1975817751 @default.
• W4384704944 cites W1998505222 @default.
• W4384704944 cites W1998564612 @default.
• W4384704944 cites W2012454301 @default.
• W4384704944 cites W2044367057 @default.
• W4384704944 cites W2048481605 @default.
• W4384704944 cites W2052363694 @default.
• W4384704944 cites W2053503845 @default.
• W4384704944 cites W2073302587 @default.
• W4384704944 cites W2081477174 @default.
• W4384704944 cites W2104853744 @default.
• W4384704944 cites W2121551893 @default.
• W4384704944 cites W2162714184 @default.
• W4384704944 cites W2165811923 @default.
• W4384704944 cites W2292538846 @default.
• W4384704944 cites W2299530520 @default.
• W4384704944 cites W2318503132 @default.
• W4384704944 cites W2327439176 @default.
• W4384704944 cites W2329960468 @default.
• W4384704944 cites W2597046269 @default.
• W4384704944 cites W2612723304 @default.
• W4384704944 cites W2761438050 @default.
• W4384704944 cites W2792742326 @default.
• W4384704944 cites W2794936416 @default.
• W4384704944 cites W2889157553 @default.
• W4384704944 cites W2912401376 @default.
• W4384704944 cites W2913388953 @default.
• W4384704944 cites W3002151074 @default.
• W4384704944 cites W3084799445 @default.
• W4384704944 cites W3086345252 @default.
• W4384704944 cites W3164547666 @default.
• W4384704944 cites W3196726451 @default.
• W4384704944 cites W3210601188 @default.
• W4384704944 cites W4224139897 @default.
• W4384704944 cites W4226418198 @default.
• W4384704944 cites W4230846903 @default.
• W4384704944 cites W4298857069 @default.
• W4384704944 cites W4318668267 @default.
• W4384704944 doi "https://doi.org/10.1093/ofid/ofad374" @default.
• W4384704944 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37539061" @default.
• W4384704944 hasPublicationYear "2023" @default.
• W4384704944 type Work @default.
• W4384704944 citedByCount "0" @default.
• W4384704944 crossrefType "journal-article" @default.
• W4384704944 hasAuthorship W4384704944A5000526175 @default.
• W4384704944 hasAuthorship W4384704944A5001007615 @default.
• W4384704944 hasAuthorship W4384704944A5002398661 @default.
• W4384704944 hasAuthorship W4384704944A5008314944 @default.
• W4384704944 hasAuthorship W4384704944A5018384098 @default.
• W4384704944 hasAuthorship W4384704944A5021697174 @default.
• W4384704944 hasAuthorship W4384704944A5026597427 @default.
• W4384704944 hasAuthorship W4384704944A5033344017 @default.
• W4384704944 hasAuthorship W4384704944A5034162338 @default.
• W4384704944 hasAuthorship W4384704944A5035485013 @default.
• W4384704944 hasAuthorship W4384704944A5036857685 @default.
• W4384704944 hasAuthorship W4384704944A5037782010 @default.
• W4384704944 hasAuthorship W4384704944A5042051995 @default.
• W4384704944 hasAuthorship W4384704944A5044869929 @default.
• W4384704944 hasAuthorship W4384704944A5057724971 @default.
• W4384704944 hasAuthorship W4384704944A5060309869 @default.
• W4384704944 hasAuthorship W4384704944A5061281956 @default.
• W4384704944 hasAuthorship W4384704944A5070081054 @default.
• W4384704944 hasAuthorship W4384704944A5070507509 @default.
• W4384704944 hasAuthorship W4384704944A5075698856 @default.
• W4384704944 hasAuthorship W4384704944A5079522703 @default.

• next